New hope for advanced cervical cancer: drug combo shows promise after immunotherapy fails
NCT ID NCT05824468
First seen Mar 11, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This study tests a combination of two drugs (zimberelimab and lenvatinib) in 30 people with advanced cervical cancer that got worse after prior immunotherapy. The goal is to see if this combo can shrink tumors or slow the disease. Participants must have tried platinum-based chemotherapy and an immune checkpoint inhibitor before joining.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Cetntre
Guangzhou, 510060, China
Conditions
Explore the condition pages connected to this study.